Moneycontrol
HomeHealth & FitnessCOVID-19 surge in Asia: Causes, symptoms and prevention tips for the JN.1 variant
Trending Topics

COVID-19 surge in Asia: Causes, symptoms and prevention tips for the JN.1 variant

JN.1 variant in India: JN.1 may not be more severe, but it spreads fast, and that’s reason enough to stay alert. Across Asia, the priority is clear: stay prepared, stay informed, and use lessons from past outbreaks to keep ahead of the virus.

May 19, 2025 / 17:47 IST
Story continues below Advertisement
COVID-19 JN.1 variant symptoms: JN.1 is a fast-spreading subvariant of Omicron, now dominant in several parts of Asia. Symptoms of COVID-19 JN.1 variant include nclude fever, dry cough, fatigue, sore throat, nasal congestion, and occasional shortness of breath

A new COVID-19 variant, JN.1, is driving a fresh wave of infections across Asia, raising concerns among health experts and governments. As a subvariant of Omicron, JN.1 is known for spreading quickly, particularly in densely populated regions. With cases rising, authorities are closely monitoring its impact and urging precautions.

According to the World Health Organization (WHO), JN.1 is classified as a variant of interest. This means it shows genetic changes that could affect its transmissibility or severity and is being closely monitored. The WHO has noted its rapid spread in several regions but confirmed there is no clear evidence that it causes more severe illness.

Story continues below Advertisement

Cases linked to JN.1 are rising sharply in parts of Asia, including India, China, Singapore, and other Southeast Asian countries. Although symptoms are generally mild, the sheer number of infections could strain hospitals. In response, many countries are increasing testing, updating travel advisories, and encouraging booster vaccinations.

Also read | Fresh Covid-19 wave hits Asia; Singapore and Hong Kong see surge: Is India at risk too?

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show